Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Palatin Technologies, Inc. Common Stock

Company price
5.36 USD -0.77 ( 12.49%)
Last update at 2026-11-17T20:53:00Z
VOLUME
53462
Market Cap
39.56M

Momentum Score

…

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.25
Low
6.15
High
52 Week Price Range
1.43
Low
5.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Palatin Technologies is a small biopharmaceutical company developing receptor-targeted peptide therapeutics and pursuing value through licensing, partnerships and commercialization arrangements. Long-term growth may be driven by clinical progress of its development programs, milestone or royalty receipts from partnered products, and new collaboration deals. Investors may find exposure to niche receptor-focused drug programs and binary upside from successful trials or licensing outcomes.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
6.12
Dividend Yield
0.31%
Revenue TTM
6.09M
Revenue Per Share
0.53
Gross Profit TTM
-18.20M
Debt / Equity
7.84
ROE
-1414.19%
Net Debt
-6.94M
ROCE
-1166.37%
Diluted EPS TTM
-2.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -32.22M -36.20M -33.60M -22.43M 35.77M
Net income -27.54M -35.81M -33.57M -22.38M 35.77M
Selling general administrative 15.29M 16.51M 17.34M 9.77M 9.70M
Gross profit 4.44M 1.25M -0.34M 0.12M 60.30M
Reconciled depreciation 0.29M 0.13M 0.05M 0.06M 0.06M
Ebit -32.75M -36.72M -33.38M -23.67M 35.74M
Ebitda -32.46M -36.59M -30.60M -23.61M 35.80M
Depreciation and amortization 0.29M 0.13M 2.78M 0.06M 0.06M
Non operating income net other - - - 1.20M 0.45M
Operating income -32.46M -36.59M -33.38M -23.61M 35.74M
Other operating expenses 38.34M 38.06M 30.41M 23.72M 24.56M
Interest expense 0.02M 0.03M 0.02M 0.02M 0.42M
Tax provision -4.67M - - 0.00M 0.00M
Interest income 0.24M 0.39M 0.21M 1.18M 0.03M
Net interest income -0.02M -0.03M -0.02M -0.02M -0.42M
Income tax expense -4.67M -0.39M -0.03M -0.04M -0.45M
Total revenue 4.85M 1.47M -0.19M 0.12M 60.30M
Total operating expenses 37.92M 37.84M 30.26M 23.72M 24.56M
Cost of revenue 0.42M 0.22M 0.15M - 14.86M
Total other income expense net 0.24M 0.39M -0.21M 1.18M 0.03M
Net income from continuing ops -27.54M -36.20M -33.60M -22.43M 35.77M
Net income applicable to common shares -27.54M -36.20M -33.60M -22.43M 35.77M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 17.94M 36.07M 67.30M 85.05M 104.74M
Other current assets 1.90M 0.67M 1.15M 0.61M 0.49M
Total liab 17.81M 19.80M 17.65M 4.88M 4.19M
Total stockholder equity 0.13M 16.27M 49.65M 80.17M 100.55M
Other current liab 10.37M 12.63M 3.72M 2.90M 0.50M
Common stock 0.12M 0.09M 2.30M 2.29M 2.27M
Capital stock 0.12M 0.09M 2.30M 2.29M 2.27M
Retained earnings -415.54M -387.99M -351.80M -318.20M -295.77M
Other liab 2.08M 2.86M 6.23M - -
Other assets 0.06M 0.06M 0.06M 0.06M 0.18M
Cash 7.99M 29.94M 60.10M 82.85M 43.51M
Cash and equivalents 7.99M 29.94M 60.10M 82.85M 43.51M
Total current liabilities 15.13M 16.26M 10.51M 3.93M 4.19M
Current deferred revenue - - 5.80M - 2.85M
Net debt -6.94M -28.79M -58.85M -81.59M -43.18M
Short term debt 0.46M 0.47M 0.35M 0.31M 0.33M
Short long term debt - - - - 0.33M
Short long term debt total 1.05M 1.15M 1.25M 1.27M 0.33M
Other stockholder equity 397.73M 404.17M 399.15M 396.08M 394.05M
Property plant equipment 1.56M 1.42M 1.33M 1.41M 0.14M
Total current assets 16.32M 34.60M 65.91M 83.59M 104.41M
Net tangible assets 0.13M 16.27M 49.65M 80.17M 100.55M
Short term investments 2.99M - - - -
Net receivables 2.92M 1.78M 1.58M 0.00M 60.27M
Long term debt - - - - 0.00M
Inventory 0.53M 0.94M 1.16M - 0.15M
Accounts payable 4.30M 3.16M 0.64M 0.72M 0.50M
Accumulated other comprehensive income -0.12M - - -2.45M -2.39M
Common stock total equity - - 2.30M 2.29M 2.27M
Preferred stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -318.20M -295.77M
Non currrent assets other 0.06M 0.06M 0.06M 0.06M 0.18M
Non current assets total 1.62M 1.47M 1.39M 1.46M 0.32M
Capital lease obligations 1.05M 1.15M 1.25M 1.27M -
Long term debt total 0.05M 0.15M 0.00M 0.00M 0.00M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -3.43M -0.26M -0.01M -0.06M -0.04M
Change to liabilities 1.11M 2.57M -0.08M 0.26M -0.97M
Total cashflows from investing activities -3.43M -0.26M -0.01M -0.06M -0.04M
Net borrowings -0.10M -0.06M -0.06M -0.83M -6.50M
Total cash from financing activities 9.90M 0.02M -0.09M -1.92M 27.33M
Change to operating activities -2.74M 0.85M -9.26M -0.23M 0.84M
Net income -27.54M -36.20M -33.60M -22.43M 35.77M
Change in cash -21.95M -30.17M -22.75M 39.34M 5.51M
Begin period cash flow 29.94M 60.10M 82.85M 43.51M 38.00M
End period cash flow 7.99M 29.94M 60.10M 82.85M 43.51M
Total cash from operating activities -28.42M -29.92M -22.65M 41.33M -21.78M
Issuance of capital stock 10.14M - 0.00M 1.58M 33.14M
Depreciation 0.29M 0.13M 0.05M 0.06M 0.06M
Other cashflows from investing activities -2.99M - - 0.00M 0.00M
Change to inventory 0.42M 0.22M -0.99M -0.52M 0.78M
Change to account receivables -1.14M -0.20M -1.58M 60.27M -60.27M
Sale purchase of stock 10.14M 0.30M 0.00M 1.58M 33.94M
Other cashflows from financing activities -0.15M 0.06M -0.09M -2.67M 0.69M
Change to netincome 1.18M 2.71M 22.80M 3.14M 3.48M
Capital expenditures 0.43M 0.26M 0.01M 0.06M 0.04M
Change receivables - - - 60.27M -60.27M
Cash flows other operating - - - 0.02M 0.09M
Cash and cash equivalents changes - - - 39.34M 5.51M
Change in working capital 0.39M 3.44M -11.90M 60.25M -61.15M
Stock based compensation 1.41M 2.51M 3.17M 3.14M 3.48M
Other non cash items -2.58M 0.20M 19.42M 0.30M 0.05M
Free cash flow -28.85M -30.18M -22.65M 41.26M -21.82M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PTN
Palatin Technologies, Inc. Common Stock
-0.77
12.49%
5.36 - - 5.61 4.25 4.82 -0.99
NVO
Novo Nordisk A/S
-0.99
2.39%
40.60 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-3.90
0.73%
533.89 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
5.36
0.56%
957.76 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Palatin Technologies, Inc. Common Stock

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Cedar Brook Corporate Center, Cranbury, NJ, United States, 08512

609 495 2200

34

Name Title Year Born
Dr. Carl Spana Ph.D. Co-Founder, Pres, CEO & Director 1962
Mr. Stephen T. Wills CPA, CPA, MST CFO, COO, Exec. VP, Treasurer & Sec. 1957
Burns McClellan VP of Investor Relations NA
Mr. Stephen A. Slusher Esq. Chief Legal Officer NA
Dr. Michael B. Raizman M.D. Chief Medical Officer NA
Mr. James E. Hattersley Sr. VP of Bus. Devel. 1960
Mr. John Dodd Ph.D. Sr. VP of Preclinical Devel. NA
Mr. Robert Jordan Sr. VP of Program Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…